X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. 1,2 Dimethyl 3 Hydroxy 4 Pyridinone
2. 1,2 Dimethyl 3 Hydroxypyrid 4 One
3. 1,2 Dimethyl 3 Hydroxypyridin 4 One
4. 1,2-dimethyl-3-hydroxy-4-pyridinone
5. 1,2-dimethyl-3-hydroxypyrid-4-one
6. 1,2-dimethyl-3-hydroxypyridin-4-one
7. 3 Hydroxy 1,2 Dimethyl 4 Pyridinone
8. 3-hydroxy-1,2-dimethyl-4-pyridinone
9. Dmohpo
10. Ferriprox
11. Hdmpp
1. 30652-11-0
2. 3-hydroxy-1,2-dimethyl-4(1h)-pyridone
3. Ferriprox
4. 3-hydroxy-1,2-dimethylpyridin-4(1h)-one
5. Cp20
6. 1,2-dimethyl-3-hydroxy-4-pyridone
7. 1,2-dimethyl-3-hydroxypyrid-4-one
8. Apo-66
9. 1,2-dimethyl-3-hydroxypyridine-4-one
10. 4(1h)-pyridinone, 3-hydroxy-1,2-dimethyl-
11. Apo-066
12. Dn-180-01-af
13. 3-hydroxy-1,2-dimethylpyridin-4-one
14. Deferipron
15. Mfcd00134497
16. Deferiprone (inn)
17. Pl-1
18. L1
19. Chebi:68554
20. 1,2-dimethyl-3-hydroxy-4(1h)-pyridinone
21. Cp-20
22. Dn-18001af
23. Nsc-758880
24. 2bty8kh53l
25. Mls000069481
26. Hk-1
27. Pl1
28. 4(1h)-pyridinone, 1,2-dimethyl-3-hydroxy-
29. Smr000059136
30. Deferiprone [inn]
31. L-1
32. Cp20 (chelating Agent)
33. Ferriprox (tn)
34. Unii-2bty8kh53l
35. Brn 1447108
36. Deferidone
37. Deferiprona
38. Deferum
39. Deferiprone [usan:inn:ban]
40. Ccris 8318
41. 1,2-dimethyl-3-hydroxy-4-pyridinone
42. 3-hydroxy-1,2-dimethyl-4-pyridinone
43. L-1[chelating Agent]
44. Opera_id_366
45. 3-hydroxy-1,2-dimethyl-4(1h)-pyridinone
46. Deferiprone [mi]
47. 4(1h)-pyridone, 3-hydroxy-1,2-dimethyl-
48. Deferiprone (usan/inn)
49. Deferiprone [usan]
50. Deferiprone [vandf]
51. Deferiprone [mart.]
52. Dsstox_cid_20666
53. Dsstox_rid_79529
54. Dsstox_gsid_40666
55. Schembl94474
56. Deferiprone [who-dd]
57. Mls000758227
58. Mls001424029
59. Mls006011689
60. Chembl70927
61. Deferiprone [ema Epar]
62. Crmd-001
63. Gtpl7456
64. Zinc6226
65. Dtxsid6040666
66. Hsdb 8335
67. Tzxkocqbrnjulo-uhfffaoysa-
68. Deferiprone [orange Book]
69. Ex-a972
70. Cp020
71. Deferiprone [ep Monograph]
72. Hms2051c05
73. Hms2232e24
74. Hms3264p17
75. Hms3393c05
76. Hms3873l13
77. Pharmakon1600-01504512
78. Bcp09606
79. Hy-b0568
80. 3-hydroxy-1,2-dimethylpyrid-4-one
81. Tox21_112429
82. Bbl036482
83. Bdbm50525976
84. Cgp-37391
85. Nsc758880
86. S4067
87. Stl559018
88. 1,2-dimetyl-3-hydroxy-4-pyridinone
89. Akos015902286
90. Ccg-100760
91. Cs-5240
92. Db08826
93. Ds-5493
94. Nc00010
95. Nsc 758880
96. 3-hydroxy-1,2-dimethyl-4- Pyridinone
97. 3-hydroxy-1,2-dimethyl-pyridin-4-one
98. Ncgc00090548-01
99. Ncgc00090548-02
100. Ncgc00090548-04
101. Ncgc00090548-05
102. Ac-33026
103. Bp-12415
104. Sy052576
105. Sbi-0207041.p001
106. Cas-30652-11-0
107. Db-047826
108. 1,2-dimethyl-3-hydroxy-4-pyridone, 99+%
109. Ft-0606424
110. H0944
111. D07416
112. 3-hydroxy-1,2-dimethyl-4(1h)-pyridone, 98%
113. Ab00572605_11
114. Ab00572605_12
115. A820470
116. Q749664
117. Sr-01000721891
118. Deferiprone 1,2-dimethyl-3-hydroxy-4-pyridone
119. Sr-01000721891-4
| Molecular Weight | 139.15 g/mol |
|---|---|
| Molecular Formula | C7H9NO2 |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 139.063328530 g/mol |
| Monoisotopic Mass | 139.063328530 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 228 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Ferriprox |
| PubMed Health | Deferiprone (By mouth) |
| Drug Classes | Heavy Metal Chelator |
| Drug Label | Ferriprox (deferiprone) tablets contain 500mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. Deferiprone has the following structural formula:Deferiprone is a white to pinkish-white crystallin... |
| Active Ingredient | Deferiprone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Apopharma |
| 2 of 2 | |
|---|---|
| Drug Name | Ferriprox |
| PubMed Health | Deferiprone (By mouth) |
| Drug Classes | Heavy Metal Chelator |
| Drug Label | Ferriprox (deferiprone) tablets contain 500mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. Deferiprone has the following structural formula:Deferiprone is a white to pinkish-white crystallin... |
| Active Ingredient | Deferiprone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Apopharma |
Iron Chelating Agents
National Library of Medicine's Medical Subject Headings. Deferiprone. Online file (MeSH, 2016). Available from, as of June 24, 2016: https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Deferiprone is included in the database.
NIH/NLM; ClinicalTrials.Gov. Available from, as of July 6, 2016: https://clinicaltrials.gov/search/intervention=DEFERIPRONE
Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. /Included in US product label/
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
/EXPL THER/ Friedreich ataxia is an inherited disorder characterized by degeneration of the peripheral and central nervous system and hypertrophic cardiomyopathy. Homozygous mutations in the frataxine (FXN) gene reduce expression of frataxin and cause accumulation of iron in the mitochondria. Deferiprone, an oral iron chelator, has been shown effective in cell and animal models of Friedreich ataxia. The results of a 6-month randomized, double blind placebo-controlled study suggested that deferiprone 20 mg/kg/day may reduce disease progression. The authors present their experience of 5 Friedreich ataxia patients treated with deferiprone (20 mg/kg/day), in addition to idebenone treatment, followed over a period of 10-24 months, under off-label authorization. The patients were monitored for laboratory parameters, cardiac assessment, neurological evaluations, and quality of life. The authors conclude that combined therapy of a low dose of deferiprone with idebenone is relatively safe, might improve neurological function, and seems to improve heart hypertrophy, warranting further studies.
PMID:27029487 Elincx-Benizri S et al; J Child Neurol 31 (8): 1036-40 (2016)
/EXPL THER/ Growing body of evidence suggests that Parkinson's disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP's involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD.
PMID:25943368 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429376 Grolez G et al; BMC Neurol 15:74 (2015)
/BOXED WARNING/ WARNING: AGRANULOCYTOSIS/NEUTROPENIA: Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. Measure the absolute neutrophil count (ANC) before starting Ferriprox therapy and monitor the ANC weekly on therapy. Interrupt Ferriprox therapy if neutropenia develops. Interrupt Ferriprox if infection develops, and monitor the ANC more frequently. Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman. ... If Ferriprox is used during pregnancy or if the patient becomes pregnant while taking Ferriprox, the patient should be apprised of the potential hazard to the fetus.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
It is not known whether deferiprone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from Ferriprox, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
Safety and effectiveness in elderly individuals have not been established. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
For more Drug Warnings (Complete) data for Deferiprone (13 total), please visit the HSDB record page.
Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.
FDA Label
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Treatment of chronic iron overload
Iron Chelating Agents
Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)
V03AC02
V03AC02
V03AC02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AC - Iron chelating agents
V03AC02 - Deferiprone
Absorption
Deferiprone is absorbed in the upper gastrointestinal tract. Absorption is rapid with maximum plasma concentrations occurring after 1 hour in the fasted state and after 2 hours in the fed state.
Route of Elimination
Within 5-6 hours of administration, more than 90% of deferiprone is eliminated from the plasma. 75 to 90% of deferiprone is excreted in the urine as the metabolite.
Volume of Distribution
In healthy patients, the volume of distribution is 1L/kg, and in thalassemia patients, the volume of distribution is 1.6L/kg.
In healthy subjects, the mean maximum concentration (Cmax) of deferiprone in serum was 20 ug/mL, and the mean total area under the concentration-time curve (AUC) was 53 ug*hr/mL following oral administration of a 1,500 mg dose of Ferriprox tablets in the fasting state. Dose proportionality over the labeled dosage range of 25 to 33 mg/kg three times per day (75 to 99 mg/kg per day) has not been studied. The elimination half life of deferiprone was 1.9 hours. The accumulation of deferiprone and its glucuronide metabolite at the highest approved dosage level of 33 mg/kg three times per day has not been studied. The volume of distribution of deferiprone is 1.6 L/kg in thalassemia patients, and approximately 1 L/kg in healthy subjects. The plasma protein binding of deferiprone in humans is less than 10%.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract, appearing in the blood within 5 to 10 minutes of oral administration. Peak serum concentrations occur approximately 1 hour after a single dose in fasted healthy subjects and patients, and up to 2 hours after a single dose in the fed state. Administration with food decreased the Cmax of deferiprone by 38% and the AUC by 10%. While a food effect cannot be ruled out, the magnitude of the exposure change does not warrant dose adjustment.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
More than 90% of deferiprone is eliminated from plasma within 5 to 6 hours of ingestion. Following oral administration, 75% to 90% is recovered in the urine in the first 24 hours, primarily as metabolite.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
/MILK/ It is not known whether deferiprone is excreted in human milk.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
For more Absorption, Distribution and Excretion (Complete) data for Deferiprone (8 total), please visit the HSDB record page.
Deferiprone is mainly metabolized by UGT1A6 to the 3-O-glucuronide metabolite. This metabolite cannot chelate iron.
In humans, the majority of the deferiprone is metabolized, primarily by UGT1A6. The contribution of extrahepatic (e.g., renal) UGT1A6 is unknown. The major metabolite of deferiprone is the 3-O-glucuronide, which lacks iron binding capability. Peak serum concentration of the glucuronide occurs 2 to 4 hours after administration of deferiprone in fasting subjects.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
The half-life is 1.9 hours.
The pharmacokinetics of deferiprone in children was assessed in 7 patients with thalassemia and iron overload aged 11 to 18 years (mean age= 15 + or - 2.7 years; median=16 years). These patients were on long term therapy with deferiprone and were thus considered to be at steady state. ... Serum levels of deferiprone were maximal approximately 2 hours after dosing and declined with a half-life of 1.8 hours; levels of deferiprone glucuronide peaked at approximately 3 hours and fell with a half-life of 2.0 hours. ...
Health Canada; Product Monograph for Ferriprox (Deferiprone) Tablets (500 mg and 1000 mg) Deferiprone Oral Solution (100 mg/mL). Drug Identification Number (DIN): 02436531 p.17 (Date of Preparation: January 22, 2015). Available from, as of July 14, 2016: https://webprod5.hc-sc.gc.ca/dpd-bdpp/start-debuter.do?lang=eng
In healthy subjects ... following oral administration of a 1,500 mg dose of Ferriprox tablets in the fasting state ... the elimination half life ... was 1.9 hours.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
Deferiprone is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Deferiprone is more selective for iron in which other metals such as zinc, copper, and aluminum have a lower affinity for deferiprone.
Deferiprone is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has a lower binding affinity for other metals such as copper, aluminum and zinc than for iron.
NIH; DailyMed. Current Medication Information for Ferriprox (Deferiprone) Tablet, Film-coated (Updated: February 2015). Available from, as of July 14, 2016: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23
Market Place
